What's Behind Bristol-Myers Squibb's High Valuation?

Shares of Bristol-Myers Squibb  (NYSE: BMY  ) have soared more than 27% since the start of this year, surpassing not only the S&P 500, but also its peers Eli Lilly (NYSE: LLY  ) and AstraZeneca (NYSE: AZN  ) . What have been the main drivers of this growth, and how is Bristol-Myers valued today compared to other stocks in this competitive industry? In the following segment, taken from The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss an important valuation metric that all investors should pay attention to and why Bristol-Myers trades at a premium to many of its peers.

One of the best parts of owning big pharma stocks like Bristol-Myers Squibb is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2603833, ~/Articles/ArticleHandler.aspx, 4/24/2014 5:20:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement